The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public.
The doctor is accused of using fake credentials for several months and performing approximately 50 procedures. This is the second time in recent months someone has been accused of impersonating a heart specialist and treating patients.
The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.
Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves.
Injuries to the esophagus remain a common complication associated with radiofrequency ablation procedures. New research suggests a device developed by S4 Medical could significantly reduce the risk of such injuries.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.
"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.
